

17th John Vane Memorial Symposium on Prostacyclin Science & Pulmonary Vascular Disease

Faculty Chair

Chris Thiemermann, Queen Mary University of London, UK

Session Chairs

Raymond Benza, The Ohio State University, Columbus, USA

Paul Corris, Newcastle University, UK

Anna Hemnes, Vanderbilt University, Nashville, USA

Marc Humbert, Université Paris-Saclay, France

Irene Lang, Medical University of Vienna, Austria

Robert Naeije, Université Libre de Bruxelles, Belgium

Olivier Sitbon, Université Paris-Saclay, France

Chris Thiemermann, Queen Mary University of London, UK

Dario Vizza, La Sapienza University of Rome, Italy

Aaron Waxman, Harvard University, Boston, USA

Jim White, University of Rochester, Rochester, USA

Brendan Whittle, Queen Mary University of London, UK

18th & 19th March 2022

The Royal Society

6-9 Carlton House Terrace, London, SW1Y 5AG, UK

CPD credits TBC

Friday, 18th March 2022

08.30-9.20 Registration, tea and coffee

09.20 Welcome
Chris Thiemermann, Queen Mary University of London, UK

Session I

Chairs: *Chris Thiemermann, Queen Mary University of London, UK*
Brendan Whittle, Queen Mary University of London, UK

09.30 New Concepts in Inflammation Research
Sussan Nourshargh, Queen Mary University of London, UK

10.00 Kinase Signalling in Pulmonary Hypertension
Ralph Schermuly, University of Giessen, Germany

10.30 Refreshments

Session II

Chairs: *Irene Lang, Medical University of Vienna, Vienna, Austria*
Dario Vizza, La Sapienza University of Rome, Rome, Italy

11.00 Portopulmonary Hypertension
Olivier Sitbon, Université Paris-Saclay, Paris, France

11.30 Pulmonary Hypertension in Patients with COPD
Dario Vizza, La Sapienza University of Rome, Rome, Italy

12.00 Defining PAH with Left Heart Phenotype
Irene Lang, Medical University of Vienna, Vienna, Austria

12.30 Lunch

Session III

- Chairs:** *Paul Corris, Newcastle University, Newcastle, UK*
Anna Hemnes, Vanderbilt University, Nashville, USA
- 14.00** Molecular Predictors of Prostacyclin Responses
Anna Hemnes, Vanderbilt University, Nashville, USA
- 14.30** Inhaled Treprostinil in Pulmonary Hypertension due to Interstitial Lung Disease.
Aaron Waxman, Brigham and Women's Hospital, Harvard Medical School, Boston, USA
- 15.00** Early and aggressive prostacyclin treatment in PAH
Roberto Badagliacca, La Sapienza University of Rome, Rome, Italy
- 15.30** Refreshments

Session IV

- Chairs:** *Raymond Benza, The Ohio State University, Columbus, USA*
Robert Naeije, Universite Libre de Bruxelles, Bruxelles, Belgium
- 16.00** Emerging Clinical Studies (TBC)
Jim White, University of Rochester, USA
- 16.30** Risk Stratification in PAH
Murali Chakinala, Washington University School of Medicine, St Louis, USA
- 17.00-18.30** Meeting adjournment and Evening Reception at the Royal Society

Saturday, 19th March 2022

08.30 Tea and coffee

Session V

Chairs: *Marc Humbert, Université Paris-Saclay, Paris, France*
Aaron Waxman, Brigham and Women's Hospital, Harvard Medical School, Boston, USA

09.30 Targeting ActRIIA ligands in Pulmonary Hypertension
Marc Humbert, Université Paris-Saclay, Paris, France

10.00 Remote Management of PAH and Risk Management
Raymond Benza, The Ohio State University, Columbus, USA

10.30 Multimodality Imaging and AI in the diagnosis and assessment of PAH
David Kiely, University of Sheffield, Sheffield, UK

11.00 Refreshments

Session VI

Chairs: *Olivier Sitbon, Université Paris-Saclay, Paris, France*
Jim White, University of Rochester, Rochester, USA

11.30 Initial Treatment Strategies and Survival in PAH
Athenais Boucly, Université Paris-Saclay, Paris, France

12.00 Imaging of the right ventricle for risk assessment and treatment in PAH
Robert Naeije, Université Libre de Bruxelles, Bruxelles, Belgium

12.30 A Global Perspective of Patient Access to Care
Paul Corris, Newcastle University, Newcastle, UK

13.00 Lunch

14.00 Close of meeting